Review Form 3

Journal Name:	**Asian Oncology Research Journal**
Manuscript Number:	**Ms_AORJ_127946**
Title of the Manuscript:	**Immunotherapy for Resistant Cancers: Review of Present and Future Directions**
Type of the Article	

<mark>PART 1:</mark> **Comments**

	Reviewer's comment	Author's Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.	**This manuscript is highly significant for the scientific community as it provides a comprehensive overview of how immunotherapy addresses resistance mechanisms in cancer treatment. It effectively integrates foundational concepts such as immunoediting and immune evasion with emerging therapies like CAR T-cell therapy, oncolytic viruses, and cancer vaccines. I appreciate its balance of theoretical insights and clinical trial outcomes, making it valuable for both researchers and clinicians. However, it could benefit from more emphasis on the practical challenges of implementing these therapies in diverse healthcare systems.**	
Is the title of the article suitable? **(If not please suggest an alternative title)**	**The title is clear and suitable. However, it could be more specific to emphasize the focus on resistance, e.g., "Immunotherapy Strategies for Overcoming Resistant Cancers: Current Trends and Future Prospects."**	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	**The abstract is comprehensive, but it could highlight key challenges such as immune-related adverse events and cost barriers. Adding these would provide a balanced view upfront.**	
Is the manuscript scientifically, correct? Please write here.	The manuscript demonstrates scientific robustness through its reliance on recent and relevant literature, thorough exploration of mechanisms like immune checkpoint pathways, and balanced discussion of therapeutic strategies. The technical depth and integration of clinical trial data reinforce its credibility. However, some claims, such as the projected cost impact of immunotherapies, require additional references or supporting data for validation.	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	The references are sufficient and up-to-date, covering pivotal studies. Suggested additions include: - Articles on the evolving role of artificial intelligence in predicting immunotherapy outcomes. - Studies exploring disparities in global access to immunotherapy. -	
Is the language/English quality of the article suitable for scholarly communications?	- The language quality is high, but minor improvements in phrasing could enhance readability. For example, some sections are overly technical and could benefit from simpler terminology for broader accessibility. - Standardizing abbreviations (e.g., "TME" for tumor microenvironment) throughout the manuscript would improve consistency. -	
Optional/General comments	- **Including patient-centric perspectives on immunotherapy challenges could broaden the scope.** - **Ethical considerations around access disparities, especially in low-income regions, should be briefly discussed.**	

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	**Kirolos Eskandar**
Department, University & Country	**Helwan University, Egypt**